Interleukin-12 inhibits graft-versus-host disease through an Fas- mediated mechanism associated with alterations in donor T-cell activation and expansion

Blood

Volumn 91, Issue 9, 1998, Pages 3315-3322

  Dey, Bimalangshu R ^a   Yang, Yong Guang ^a   Szot, Gregory L ^a   Pearson, Denise A ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 12; VERY LATE ACTIVATION ANTIGEN;

ALLOIMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HLA MATCHING; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION;

EID: 0032079469     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3315.3315_3315_3322     Document Type: Article

References (45)

1. Gale RP: Graft-versus-host disease. Immunol Rev 88:193, 1985
2. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran TJ, Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989
3. Clift RA, Storb R: Histoincompatible bone marrow transplants in humans. Ann Rev Immunol 5:43, 1987
4. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney C, Martin PJ, Mickelson E, Nisperos B, O'Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320:197, 1989
5. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985
6. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ: Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Transplantation 43:842, 1987
7. Sykes M, Szot GL, Nguyen PL, Pearson DA: Interleukin-12 inhibits murine graft-vs-host disease. Blood 86:2429, 1995
8. Yang Y-G, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M: Interleukin-12 preserves the graft-vs-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-vs-host disease in mice. Blood 90:4651, 1997
9. Wang M-G, Szebeni J, Pearson DA, Szot GL, Sykes M: Inhibition of graft-vs-host disease (GVHD) by IL-2 treatment is associated with altered cytokine production by expanded GVH-reactive CD4+ helper cells. Transplantation 60:481, 1995
10. Sykes M, Romick ML, Sachs DH: Interleukin 2 prevents graft-vs-host disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87:5633, 1990
11. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to human Leu3/T4 molecule. J Immunol 131:2445, 1983
12. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980
13. Sykes M, Abraham VS, Harty MW, Pearson DA: IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 150:197, 1993
14. Sykes M, Romick ML, Hoyles KA, Sachs DH: In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 171:645, 1990
15. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979
16. Ozato K, Mayer NM, Sachs DH: Monoclonal antibodies to mouse major histocompatibility complex antigens IV. A series of hybridoma clones producing anti-H-2d antibodies and an examination of expression of H-2d antigens on the surface of these cells. Transplantation 34:113, 1982
17. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 126:1614, 1981
18. Simon MM, Eichmann K: Limiting dilution analysis of alloreactive T helper cells: Precursor frequencies similar to that of alloreactive cytotoxic T cells. Immunobiology 164:78, 1983
19. Webb SR, Hutchinson J, Hayden K, Sprent J: Expansion/deletion of mature T cells exposed to endogenous superantigens in vivo. J Immunol 152:586, 1994
20. Sprent J, Webb S: Intrathymic and extrathymic clonal deletion of T cells. Curr Opin Immunol 7:196, 1995
21. Kabelitz D, Pohl T, Pechold K: Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 14:338, 1993
22. Russell JH: Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol 7:382, 1995
23. Yang Y-G, Dey B, Sergio JJ, Sykes M: IL-12 prevents severe acute GVHD and GVHD-associated immune dysfunction in a full MHC haplotype-mismatched murine bone marrow transplantation model. Transplantation 64:1343, 1997
24. Mehrotra PT, Wu D, Crim JA, Mostowki HS, Siegel JP: Effects of IL-12 on the generation of cytotoxic activity in human CDS+ T lymphocytes. J Immunol 151:2444, 1993
25. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U, Stern AS: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874, 1991
26. Orange JS, Wolf SF, Biron CA: Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 152:1253, 1994
27. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA: Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocortioids. J Exp Med 181:901, 1995
28. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ: Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 173:79, 1991
29. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G: Induction of Interferon gamma production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J Exp Med 173:869, 1991
30. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Getely MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697, 1994
31. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G: Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 148:92, 1992
32. Macatonia SE, Hsieh C-S, Murphy KM, O'Garra A: Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from ab-TCR transgenic mice: IL-12 can substitute for macrophages to stimulate IFN-gamma production. Int Immunol 5:1119, 1993
33. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041, 1993
34. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S: Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing IFN-gamma and TNF-alpha secretion. Blood 84:2622, 1994
35. + lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J Immunol 159:2599, 1997
36. Brok HPM, Heidt PJ, Van der Meide PH, Zurcher C, Vossen JM: Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 151:6451, 1993
37. Sykes M, Harty MW, Szot GL, Pearson DA: Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83:2560, 1994
38. Ju S-T, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A: Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 91:4185, 1994
39. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanism of T cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
40. Yanagida T, Kato T, Igarashi O, Inoue T, Nariuchi H: Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol 152:4919, 1994
41. Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353:858, 1991
42. Kneitz B, Herrmann T, Yonehara S, Schimpl A: Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in IL-2-deficient mice. Eur J Immunol 25:2572, 1995
43. Smith KA: Interleukin-2: Inception, impact, and implications. Science 240:1169, 1988
44. Willerford D, Chen J, Ferry JA, Davidson L, Alt F: IL-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521, 1995
45. Van Parijs L, Biuckians A, Ibragimov A, Alt FW, Willerford DM, Abbas AK: Functional responses and apoptosis of CD25 (IL-2Ra)-deficient T cells expressing a transgenic antigen receptor. J Immunol 158:3738, 1997